Results 51 - 60 of 208 : Previous 2 3 4 5 6 7 8 9 10 Next
Erbitux's Deceptively Disappointing Results
Poorly received lead-drug data batters ImClone shares.
The pharmaceutical's assets are worth more than Wall Street thinks.
These gems aren't easy to find, but they are worth the struggle.
The pharmaceutical cancels a troubled clinical trial.
All Is Not Lost for AstraZeneca's Iressa
AstraZeneca's Iressa gets a little pep back.
I Like Big Moats and I Cannot Lie
You other investors can't deny.
What Will Icahn Do With Amylin?
Sell or advocate for management changes seems to be his M.O.
Is Merck Keeping Its Enemies Close?
The drugmaker strikes a deal with an Indian generic company.
Merck's best hope at recovery fails approval by the FDA.
Weakening currency barely redeems the pharmaceutical's Q1 numbers.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK